Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AGXT | P21549 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27717492 | 0.87 | TAAR1 (0.61) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL5153864 | 0.86 | CHRM2 (0.48) | CHRM2CHRM1CHRM3 | |
| SCHEMBL920589 | 0.84 | MAOB (0.67) | MAOBABCB1HTR1ADRD2IDO1 | |
| SCHEMBL12945605 | 0.83 | TAAR1 (0.56) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL5535801 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1CHRM3MAOB | |
| SCHEMBL833408 | 0.80 | KCNH2 (0.49) | TAAR1SIGMAR1AOC3MAOBHRH3 | |
| SCHEMBL5542037 | 0.79 | TAAR1 (0.47) | TAAR1MAOBIDO1AGXT | |
| SCHEMBL1283338 | 0.79 | TAAR1 (0.47) | TAAR1MAOBSLC2A1IDO1AGXT | |
| SCHEMBL28376353 | 0.78 | KCNH2 (0.46) | TAAR1MAOB | |
| SCHEMBL2067498 | 0.78 | ATM (0.51) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1880720-B1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2013-02-13 | — | — | EP | claimed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | claimed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | claimed |
| US-8497397-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-30 | — | — | US | disclosed |
| EP-1880720-B1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
| US-8143446-B2 | Substituted acrylamide derivative and pharmaceutical composition comprising the same | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACR, NAT1, C1S | TAAR1 260/4885CHRM2 195/4885CHRM1 152/4885 |
| US-20120220593-A1 | Substituted Acrylamide Derivative and Pharmaceutical Composition Comprising the Same | ACR, NAT1, C1S | TAAR1 260/4885CHRM2 195/4885CHRM1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.